Global B2B Pharmaceutical Sourcing · Dossier Licensing · Named-Patient Access
💬 WhatsApp · Sign in · Register
Flibanserin tablet bulk supplier for pharma manufacturers

Flibanserin Tablet 100 mg Suppliers & Bulk Manufacturers

Available Forms: Tablet

Available Strengths: 100 mg

Reference Brands: Addyi(US)

Category: Sexual Wellness

Flibanserin is a serotonin receptor modulator that increases sexual desire by balancing neurotransmitters involved in mood and arousal. It reduces hypoactive sexual desire disorder (HSDD) symptoms, improves libido, and enhances intimacy. Benefits include improved sexual motivation, better quality of life, and increased confidence for women experiencing sexual desire issues.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

Product Description:

Flibanserin tablets, marketed as Addyi, are approved in the US by the FDA for the treatment of premenopausal women with hypoactive sexual desire disorder (HSDD). Regulatory requirements include a comprehensive dossier with clinical efficacy, safety data, manufacturing quality, and pharmacovigilance plans. In the US, the FDA conducts detailed review processes, while the EU’s EMA assesses compliance with regional safety and quality standards—though approval in Europe remains pending or varies by country. 

Flibanserin Tablet — third party manufacturing & bulk supply

Flibanserin Tablet 100 mg is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.
Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.
Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Flibanserin Tablet is supplied as Tablet — an oral solid dosage form, so the indicative MOQ is 200,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Flibanserin Tablet listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Flibanserin Tablet →
Back to Listing

Frequently Asked Questions

Flibanserin tablet is listed as Tablet in 100 mg. Further strengths and pack presentations are confirmed with the manufacturer at RFQ stage.

Flibanserin tablet is referenced against Addyi(US). Reference brands are shown for identification only and remain the property of their respective trademark owners.

Related Products

Mesterolone Tablets

Strength:
25 mg

Form: Tablet

Reference Brands: Proviron(US)

View Details
Bremelanotide Sq Injection

Strength:
1.75 mg

Form: Injection(SQ)

Reference Brands: Vyleesi (US)

View Details
Testosterone Patches

Strength:
2.5 mg/24 hours, 5 mg/24 hours, and 4 mg/24 hours

Form: Patches

Reference Brands: Androderm(US), Testogel(EU)

View Details
Estrogen + Levonorgestrel. Patch

Strength:
50 μg estradiol + 10 mg levonorgestrel.

Form: Patch

Reference Brands: Climara(EU & US)

View Details
Tadalafil Tablets

Strength:
2.5 mg, 5 mg, 10 mg, 20 mg and 40 mg(P. Hypertension)

Form: Tablet

Reference Brands: Cialis(US & EU),Adcirca(US)

View Details
Vardenafil Tablet

Strength:
5 mg, 10 mg, 20 mg

Form: Tablet

Reference Brands: Levitra, Staxyn(US & EU)

View Details
Avanafil Tablets

Strength:
50 mg, 100 mg, 200 mg

Form: Tablet

Reference Brands: Stendra(US)

View Details
Alprostadil Injection

Strength:
10 µg and 20 µg

Form: Injection

Reference Brands: Caverject, Edex(US)

View Details
Enquire Now

Quick Response Guaranteed | Verified Suppliers

Subscribe to Our Newsletter

Stay updated on pharma trends and sourcing opportunities.

Please enter the correct answer.
This website uses cookies to ensure you get the best experience. By using our site, you agree to our Privacy Policy.